Entocort

DRUG4 trials

Sponsors

Medical University Of Warsaw, Padagis LLC, University of Kansas Medical Center

Conditions

Children primary nephropathy IgACrohn's DiseaseDiarrhea

Phase 2

Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

TerminatedNCT02991768

University of Kansas Medical CenterDiarrhea

Start: 2017-01-27End: 2019-04-26Updated: 2024-09-19

Phase 3

Safety Study of Entocort for Children With Crohn's Disease

CompletedNCT01444092

Padagis LLCCrohn's Disease

Start: 2011-11-30End: 2014-09-30Updated: 2022-01-06

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

CompletedNCT01453946

Padagis LLCCrohn's Disease

Start: 2011-12-31End: 2014-02-28Updated: 2022-01-06

SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.

Not yet recruitingCTIS2024-518759-45-00

Medical University Of WarsawChildren primary nephropathy IgA

Target: 120Updated: 2025-11-25

Related Papers

Enteric-coated budesonide for the induction and maintenance of remission of Crohn’s disease in children

Current Medical Research and Opinion2017-04-1914 citations